SY   WI-38/Fao hybrid-B9/R
DR   BTO; BTO:0006310
DR   Wikidata; Q107117447
RX   PubMed=12606785;
RX   PubMed=17276572;
CC   Doubling time: 2.9 +- 0.3 days (PubMed=17276572).
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
OX   NCBI_TaxID=9606; ! Homo sapiens
OX   NCBI_TaxID=10116; ! Rattus norvegicus
CA   Hybrid cell line
DT   Created: 20-05-21; Last updated: 23-09-21; Version: 2
RX   PubMed=12606785; DOI=10.1124/mol.63.3.742;
RA   Briz O., Macias R.I.R., Vallejo M., Silva A., Serrano M.A.,
RA   Marin J.J.G.;
RT   "Usefulness of liposomes loaded with cytostatic bile acid derivatives
RT   to circumvent chemotherapy resistance of enterohepatic tumors.";
RL   Mol. Pharmacol. 63:742-750(2003).
RX   PubMed=17276572; DOI=10.1016/j.tox.2006.12.022;
RA   Briz O., Cassio D., Blazquez A.G., Grosse B., Serrano M.A.,
RA   Marin J.J.G.;
RT   "Characterization of WIF-B9/R cells as an in vitro model with
RT   hepatocyte-like polarity and enhanced expression of canalicular ABC
RT   transporters involved in phase III of hepatic detoxification.";
RL   Toxicology 232:24-36(2007).